TapImmune to Present at the Maidstone Life Sciences "Cancer Immunotherapy: A Long-Awaited Reality" on Thursday March 26, 2015

SEATTLE, Mar. 25, 2015 /PRNewswire/ --TapImmune Inc. (OTCBB: TPIV), a clinical stage immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious diseases, announced today that Dr. Glynn Wilson, Chairman & CEO  will present a corporate update at the Fifth Annual: "Cancer Immunotherapy: A Long-Awaited Reality" conference at the New York Academy of Medicine in New York City, at 4.30 Eastern Time ET.  A live audio webcast of Dr. Wilson's presentation will be available on TapImmune's website at www.tapimmune.com and will be archived on the website for 30 days following the event.

Dr. Wilson will also participate as an invited panellist in a discussion on "What is the Role of Cancer Vaccines in an Environment Overwhelmed by Checkpoint Inhibitors and T Cell Immunotherapies"?

About MaidStone Life Sciences Cancer Immunotherapy Conference
On Thursday, March 26, 2015 from 8:00 a.m. to 6:30 p.m. Eastern Time, MaidStone Life Sciences LLC will host the Fifth Annual "Cancer Immunotherapy: A Long-Awaited Reality" conference at the New York Academy of Medicine in New York City. This unique, single-day conference event unites founding visionary researchers, clinicians, business leaders, key investors, and other stakeholders to engage in discussions, exchange information, highlight opportunities, and showcase leading companies in the field of cancer immunotherapy.

About TapImmune Inc.

TapImmune Inc. is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company's website at www.tapimmune.com for details. 

Forward-Looking Statement Disclaimer 

This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.

CONTACTS:

TapImmune Inc.
Glynn Wilson, Ph.D.
Chairman & CEO
+1-(866)-359-7541

PCG Advisory
Kirin M. Smith
Chief Operating Officer
+1-(646)-863-6519

Sean Leous
Chief Communications Officer
+1-(646)-863-8998
www.pcgadvisory.com

J. Streicher Capital, LLC
Robert Giordano
+1-917-327-3938

SOURCE TapImmune Inc.

Related Links

http://www.tapimmune.com